Positions

Overview

  • Dr. Kulkarni received her initial medical training and internship at Bangalore Medical College and Research Institute with graduate studies completed at Harvard T.H. Chan School of Public Health. She completed a residency in Internal Medicine at Wayne State University. After completing her residency, Dr. Kulkarni began a clinical and research fellowship at UAB in 2013. Following this fellowship, she joined the UAB faculty in June 2016 as Instructor of Medicine.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Update in Pulmonary Fibrosis 2018 2019
    2019 Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. 2019
    2019 Preoperative Evaluation of Patients With Interstitial Lung Disease 2019
    2019 Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis 2019
    2019 Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis 2019
    2017 Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival 2016
    2016 Matrix remodeling in pulmonary fibrosis and emphysema 2016
    2016 Flexible bronchoscopy is safe and effective in adult subjects supported with extracorporeal membrane oxygenation 2016
    2016 Oxidative modifications of protein tyrosyl residues are increased in plasma of human subjects with interstitial lung disease 2016
    2016 Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections 2016
    2016 Extracorporeal membrane oxygenation in adults: A practical guide for internists 2016
    2015 Heme oxygenase-1 protects Corexit 9500ainduced respiratory epithelial injury across species 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2014 Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation 2014
    2013 Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide 2013

    Research Overview

  • Dr. Kulkarni's research interests include Interstitial Lung Disease and Pulmonary Fibrosis.
  • Principal Investigator On

    Investigator On

  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2024
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2022
  • Private Grant  awarded by MALLINCKRODT ARD, INC 2018 - 2021
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2018 - 2020
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University 2019 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2018 - 2020
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh 2018 - 2020
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018 - 2020
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh 2017 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2019
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2015 - 2018
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2018
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2017
  • Full Name

  • Tejaswini Kulkarni